The Return of the mTOR Inhibitors: Getting it Right in Patients After Cardiac Transplantation

J Am Coll Cardiol. 2018 Feb 13;71(6):651-653. doi: 10.1016/j.jacc.2017.12.033.

Authors

Howard J Eisen¹, S Farhan Hasni², Denise Wang²

Affiliations

¹ Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania. Electronic address: heisen@drexelmed.edu.
² Division of Cardiology, Drexel University College of Medicine, Philadelphia, Pennsylvania.

PMID: 29420961
DOI: 10.1016/j.jacc.2017.12.033

No abstract available

Keywords: cardiac allograft vasculopathy; heart transplantation; mTOR.

Publication types

Editorial
Comment

MeSH terms

Graft Rejection
Heart Transplantation*
Humans
Sirolimus*
TOR Serine-Threonine Kinases

Substances

MTOR protein, human
TOR Serine-Threonine Kinases
Sirolimus